Keywords: Roche, MabThera, Vacaville manufacturing site, Contaminant, Non-Hodgkin's lymphoma, Rheuatoid arthritis, EMA
EMA confirms Roche's MabThera made at Vacaville site poses no health risk
Article | 28 May 2012
Following a quality review of the genetically engineered monoclonal antibody MabThera, the European Medicines Agency's Committee for Medicinal Products for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
